Our Product Pipeline
Xention is using its technology to develop a portfolio of drug candidates in the area of atrial fibrillation. Our approach allows us to:
- Accelerate the discovery of ion channel active drugs with preferred modes of action and high activity and selectivity;
- Assemble the development expertise to rapidly progress programmes to clinical proof of concept; and
- Reduce attrition rates in the development process
